Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancerResearch in context

Pinar Kanlikilicer; Recep Bayraktar; Merve Denizli; Mohammed H. Rashed; Cristina Ivan; Burcu Aslan; Rahul Mitra; Kubra Karagoz; Emine Bayraktar; Xinna Zhang; Cristian Rodriguez-Aguayo; Amr Ahmed El-Arabey; Nermin Kahraman; Seyda Baydogan; Ozgur Ozkayar; Michael L. Gatza; Bulent Ozpolat; George A. Calin; Anil K. Sood; Gabriel Lopez-Berestein

EBioMedicine (Dec 2018)

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancerResearch in context

Pinar Kanlikilicer,
Recep Bayraktar,
Merve Denizli,
Mohammed H. Rashed,
Cristina Ivan,
Burcu Aslan,
Rahul Mitra,
Kubra Karagoz,
Emine Bayraktar,
Xinna Zhang,
Cristian Rodriguez-Aguayo,
Amr Ahmed El-Arabey,
Nermin Kahraman,
Seyda Baydogan,
Ozgur Ozkayar,
Michael L. Gatza,
Bulent Ozpolat,
George A. Calin,
Anil K. Sood,
Gabriel Lopez-Berestein

Affiliations

Pinar Kanlikilicer: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Recep Bayraktar: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Merve Denizli: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Mohammed H. Rashed: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cristina Ivan: Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Burcu Aslan: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Rahul Mitra: Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Kubra Karagoz: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
Emine Bayraktar: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Xinna Zhang: Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cristian Rodriguez-Aguayo: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Amr Ahmed El-Arabey: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Nermin Kahraman: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Seyda Baydogan: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Ozgur Ozkayar: Hacettepe University, Ankara, Turkey
Michael L. Gatza: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
Bulent Ozpolat: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
George A. Calin: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Anil K. Sood: Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Gabriel Lopez-Berestein: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Corresponding author at: Department of Experimental Therapeutics, 1901 East Road, Unit 1950, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Journal volume & issue: Vol. 38
pp. 100 – 112

Abstract

Read online

Background: Circulating miRNAs are known to play important roles in intercellular communication. However, the effects of exosomal miRNAs on cells are not fully understood. Methods: To investigate the role of exosomal miR-1246 in ovarian cancer (OC) microenvironment, we performed RPPA as well as many other in vitro functional assays in ovarian cancer cells (sensitive; HeyA8, Skov3ip1, A2780 and chemoresistant; HeyA8-MDR, Skov3-TR, A2780-CP20). Therapeutic effect of miR-1246 inhibitor treatment was tested in OC animal model. We showed the effect of OC exosomal miR-1246 uptake on macrophages by co-culture experiments. Findings: Substantial expression of oncogenic miR-1246 OC exosomes was found. We showed that Cav1 gene, which is the direct target of miR-1246, is involved in the process of exosomal transfer. A significantly worse overall prognosis were found for OC patients with high miR-1246 and low Cav1 expression based on TCGA data. miR-1246 expression were significantly higher in paclitaxel-resistant OC exosomes than in their sensitive counterparts. Overexpression of Cav1 and anti-miR-1246 treatment significantly sensitized OC cells to paclitaxel. We showed that Cav1 and multi drug resistance (MDR) gene is involved in the process of exosomal transfer. Our proteomic approach also revealed that miR-1246 inhibits Cav1 and acts through PDGFβ receptor at the recipient cells to inhibit cell proliferation. miR-1246 inhibitor treatment in combination with chemotherapy led to reduced tumor burden in vivo. Finally, we demonstrated that when OC cells are co-cultured with macrophages, they are capable of transferring their oncogenic miR-1246 to M2-type macrophages, but not M0-type macrophages. Interpretation: Our results suggest that cancer exosomes may contribute to oncogenesis by manipulating neighboring infiltrating immune cells. This study provide a new mechanistic therapeutic approach to overcome chemoresistance and tumor progression through exosomal miR-1246 in OC patients. Keywords: Exosome, oncomiR, miR-1246, Ovarian cancer, Cav1, P-gp

Published in EBioMedicine

ISSN: 2352-3964 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Medicine (General)
Website: http://www.journals.elsevier.com/ebiomedicine/

About the journal